Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899882 | PMC |
| http://dx.doi.org/10.12669/pjms.38.ICON-2022.5770 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Polymer-free versus biodegradable-polymer drug-eluting stent in patients undergoing percutaneous coronary intervention: an assessor-blind, non-inferiority, randomised controlled trial.
EuroIntervention
January 2025
Department of Advanced Biomedical Sciences, University of Naples "Federico II", Naples, Italy.
Background: Few data are available on polymer-free drug-eluting stents in patients undergoing percutaneous coronary intervention (PCI).
Aims: We aimed to determine the efficacy and safety of a polymer-free amphilimus-eluting stent (AES), using a reservoir-based technology for drug delivery, compared with a biodegradable-polymer everolimus-eluting stent (EES).
Methods: This was a randomised, investigator-initiated, assessor-blind, non-inferiority trial conducted at 14 hospitals in Italy (ClinicalTrials.
Safety, tolerability, pharmacokinetics, and antimalarial activity of MMV533: a phase 1a first-in-human, randomised, ascending dose and food effect study, and a phase 1b Plasmodium falciparum volunteer infection study.
Lancet Infect Dis
December 2024
MMV Medicines for Malaria Venture, Geneva, Switzerland.
Background: Novel antimalarials are needed to address emerging resistance to artemisinin and partner drugs. We did two trials to evaluate safety, tolerability, pharmacokinetics, and activity against blood stage Plasmodium falciparum for the drug candidate MMV533.
Methods: A phase 1a first-in-human (FIH) trial was conducted at Nucleus Network (Melbourne, VIC, Australia).
Degradable starch microspheres transarterial chemoembolization (DSM-TACE) in patients with unresectable hepatocellular carcinoma: results from the Prospective Multicenter Observational HepaStar Trial.
Eur Radiol
December 2024
Clinic of Radiology, University Hospital of Münster, Albert-Schweitzer Campus 1, 48149, Münster, Germany.
Objectives: Despite increasing interest, prospective data on the use of degradable starch microsphere-transarterial chemoembolization (DSM-TACE) in the management of patients with unresectable HCC are still scarce. The objective of the HepaStar study was to collect prospective safety and effectiveness data in a prospective multicenter observational study.
Materials And Methods: Between January 2017 and December 2022, consecutive participants with unresectable or recurrent HCC treated with DSM-TACE as standard of care at 6 participating centers in Europe were enrolled.
Tackling algorithmic bias and promoting transparency in health datasets: the STANDING Together consensus recommendations.
Lancet Digit Health
January 2025
University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, Birmingham, UK; Centre for Patient Reported Outcomes Research, School of Health Sciences, College of Medical and Dental Sciences, Birmingham, UK; University of Birmingham, Birmingham, UK. Electronic address:
Article Synopsis
- There is a significant risk of reinforcing existing health inequalities in AI health technologies due to biases, primarily stemming from the datasets used.
- The STANDING Together recommendations focus on transparency in health datasets and proactive evaluation of their impacts on different population groups, informed by a comprehensive research process with over 350 global contributors.
- The 29 recommendations are divided into guidance for documenting health datasets and strategies for using them, aiming to identify and reduce algorithmic biases while promoting awareness of the inherent limitations in all datasets.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!